| Literature DB >> 27239676 |
Olivier Núñez1,2, Pablo Fernández-Navarro1,2, Iván Martín-Méndez3, Alejandro Bel-Lan3, Juan F Locutura3, Gonzalo López-Abente4,5.
Abstract
Spatio-temporal cancer mortality studies in Spain have revealed patterns for some tumours which display a distribution that is similar across the sexes and persists over time. Such characteristics would be common to tumours that shared risk factors, including the chemical soil composition. The objective of the present study is to assess the association between levels of chromium and arsenic in soil and the cancer mortality. This is an ecological cancer mortality study at municipal level, covering 861,440 cancer deaths in 7917 Spanish mainland towns from 1999 to 2008. Chromium and arsenic topsoil levels (partial extraction) were determined by ICP-MS at 13,317 sampling points. To estimate the effect of these concentrations on mortality, we fitted Besag, York and Mollié models, which included, as explanatory variables, each town's chromium and arsenic soil levels, estimated by kriging. In addition, we also fitted geostatistical-spatial models including sample locations and town centroids (non-aligned data), using the integrated nested Laplace approximation (INLA) and stochastic partial differential equations (SPDE). All results were adjusted for socio-demographic variables and proximity to industrial emissions. The results showed a statistical association in men and women alike, between arsenic soil levels and mortality due to cancers of the stomach, pancreas, lung and brain and non-Hodgkin's lymphomas (NHL). Among men, an association was observed with cancers of the prostate, buccal cavity and pharynx, oesophagus, colorectal and kidney. Chromium topsoil levels were associated with mortality among women alone, in cancers of the upper gastrointestinal tract, breast and NHL. Our results suggest that chronic exposure arising from low levels of arsenic and chromium in topsoil could be a potential risk factor for developing cancer.Entities:
Keywords: Cancer mortality; Epidemiology; Geochemistry; INLA; SPDE; Spatial data
Mesh:
Substances:
Year: 2016 PMID: 27239676 PMCID: PMC5010621 DOI: 10.1007/s11356-016-6806-y
Source DB: PubMed Journal: Environ Sci Pollut Res Int ISSN: 0944-1344 Impact factor: 4.223
Fig. 1Topsoil sampling sites in mainland Spain (upper). Triangulation of mainland Spain (lower): orange points denote soil sampling locations and green points, municipal centroids
Study of arsenic and chromium topsoil levels (mg kg−1), in interpolation by towns and by strata of proximity to industrial emissions
|
| Mean ± SD | Min | P(25) | P(50) | P(75) | Max | |
|---|---|---|---|---|---|---|---|
| All samples (13317) | |||||||
| As | 15.060 ± 40.517 | 0.100 | 5.300 | 9.000 | 15.300 | 2510.000 | |
| Cr | 29.790 ± 45.144 | 0.500 | 15.600 | 23.200 | 33.800 | 2100.000 | |
| Interpolation by towns | |||||||
| As | 7917 | 13.790 ± 7.173 | 1.000 | 9.106 | 12.810 | 16.970 | 99.370 |
| Cr | 7917 | 26.230 ± 10.161 | 6.458 | 20.230 | 24.990 | 29.860 | 243.700 |
| Towns without emissions at <5 km | |||||||
| As | 7037 | 12.650 ± 7.267 | 1.000 | 8.976 | 12.650 | 16.710 | 99.370 |
| Towns with emissions at <5 km | |||||||
| As | 880 | 14.560 ± 6.330 | 1.421 | 9.947 | 14.560 | 18.290 | 42.210 |
| Towns without emissions at <5 km | |||||||
| Cr | 6827 | 26.043 ± 10.256 | 6.643 | 20.140 | 24.840 | 29.580 | 243.700 |
| Towns with emissions at <5 km | |||||||
| Cr | 1090 | 27.402 ± 9.469 | 6.458 | 21.280 | 25.970 | 31.830 | 81.100 |
N number of towns
Fig. 2Municipal distribution of chromium and arsenic topsoil concentrations in mainland Spain. Chromium concentrations (mg kg−1) (upper); arsenic concentrations (mg kg−1) (lower)
Fig. 3BYM modelling of oesophageal cancer mortality in men (left) and women (right) over a 10-year period. The maps depict the posterior mean of relative risk for every town. Spain 1999–2008
Summary of the estimates of the effect (RR) of chromium topsoil levels, categorised in quartiles, on mortality due to different tumour types, by sex
| Cancer site | Men | Women | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unadjusted | Adjusted | Unadjusted | Adjusted | |||||||||
| RR | 95 % | CI | RR | 95 % | CI | RR | 95 % | CI | RR | 95 % | CI | |
| Buccal cavity and pharynx | ||||||||||||
| Approach A q2a | 0.996 | 0.926–1.071 | 1.050 | 0.977–1.128 | 1.014 | 0.898–1.144 | 1.061 | 0.944–1.190 | ||||
| q3 | 0.973 | 0.901–1.050 | 1.053 | 0.981–1.131 | 0.994 | 0.879–1.124 | 1.044 | 0.931–1.170 | ||||
| q4 | 0.947 | 0.875–1.026 | 1.025 | 0.958–1.096 | 1.105 | 0.979–1.242 |
|
| ||||
| Trend testb | 0.981 | 0.956–1.007 | 1.006 | 0.984–1.027 | 1.033 | 0.993–1.072 |
|
| ||||
| Approach B SPDEc | 0.970 | 0.900–1.037 | 0.938 | 0.835–1.024 | 1.096 | 0.967–1.233 |
|
| ||||
| Oesophagus | ||||||||||||
| Approach A q2a | 0.949 | 0.883–1.020 | 0.932 | 0.867–1.002 | 0.945 | 0.798–1.120 | 0.942 | 0.796–1.115 | ||||
| q3 | 0.883 | 0.818–0.953 | 0.889 | 0.827–0.955 | 0.993 | 0.838–1.177 | 1.021 | 0.867–1.203 | ||||
| q4 | 0.947 | 0.875–1.025 | 0.954 | 0.891–1.021 |
|
|
|
| ||||
| Trend testb | 0.981 | 0.955–1.006 | 0.985 | 0.964–1.007 |
|
|
|
| ||||
| Approach B PDE c | 0.978 | 0.893–1.060 | 0.990 | 0.901–1.129 | 1.254 | 0.989–1.497 | 1.263 | 0.991–1.508 | ||||
| Liver | ||||||||||||
| Approach A q2a |
|
| 1.003 | 0.926–1.086 | 0.973 | 0.853–1.110 | 0.864 | 0.761–0.980 | ||||
| q3 | 1.027 | 0.934–1.130 | 0.944 | 0.871–1.022 | 1.020 | 0.889–1.172 | 0.921 | 0.814–1.041 | ||||
| q4 | 1.097 | 0.992–1.213 | 0.982 | 0.911–1.059 | 1.041 | 0.902–1.201 | 0.935 | 0.833–1.049 | ||||
| Trend testb | 1.021 | 0.989–1.055 | 0.990 | 0.967–1.014 | 1.017 | 0.971–1.066 | 0.989 | 0.953–1.026 | ||||
| Approach B SPDEc | 1.026 | 0.930–1.151 | 1.051 | 0.948–1.197 | 1.050 | 0.905–1.198 | 1.020 | 0.891–1.184 | ||||
| Larynx | ||||||||||||
| Approach A q2a | 0.930 | 0.864–1.001 | 0.944 | 0.879–1.013 | 1.122 | 0.871–1.444 | 1.188 | 0.909–1.550 | ||||
| q3 | 0.965 | 0.893–1.042 | 1.009 | 0.941–1.082 | 1.116 | 0.866–1.435 | 1.206 | 0.925–1.571 | ||||
| q4 | 0.930 | 0.858–1.008 | 1.012 | 0.947–1.081 | 1.175 | 0.954–1.453 | 1.188 | 0.940–1.507 | ||||
| Trend testb | 0.982 | 0.957–1.008 | 1.011 | 0.990–1.032 | 1.049 | 0.982–1.121 | 1.048 | 0.974–1.127 | ||||
| Approach B SPDEc | 0.963 | 0.827–1.068 | 0.990 | 0.905–1.074 |
|
|
|
| ||||
| Pleura | ||||||||||||
| Approach A q2a | 1.052 | 0.840–1.318 | 0.970 | 0.777–1.209 | 0.951 | 0.701–1.291 | 0.879 | 0.666–1.157 | ||||
| q3 | 1.192 | 0.944–1.508 | 1.223 | 0.990–1.51 | 1.162 | 0.866–1.554 |
|
| ||||
| q4 | 1.099 | 0.856–1.408 | 1.046 | 0.854–1.282 | 1.273 | 0.961–1.690 | 1.239 | 0.989–1.557 | ||||
| Trend testb | 1.037 | 0.957–1.123 | 1.030 | 0.967–1.098 |
|
|
|
| ||||
| Approach B SPDEc | 1.182 | 0.891–1.515 | 1.201 | 0.915–1.746 |
|
|
|
| ||||
| Breast | ||||||||||||
| Approach A q2a | 1.028 | 0.986–1.072 |
|
| ||||||||
| q3 | 0.992 | 0.949–1.036 | 1.015 | 0.977–1.053 | ||||||||
| q4 | 1.007 | 0.961–1.054 |
|
| ||||||||
| Trend testb | 0.998 | 0.984–1.013 |
|
| ||||||||
| Approach B SPDEc | 0.972 | 0.927–1.022 | 0.976 | 0.934–1.020 | ||||||||
| Uterus | ||||||||||||
| Approach A q2a | 0.989 | 0.930–1.051 | 1.022 | 0.963–1.086 | ||||||||
| q3 | 0.991 | 0.930–1.055 | 1.031 | 0.971–1.094 | ||||||||
| q4 | 1.046 | 0.982–1.113 |
|
| ||||||||
| Trend testb | 1.016 | 0.996–1.037 |
|
| ||||||||
| Approach B SPDEc |
|
| 1.026 | 0.963–1.092 | ||||||||
| Kidney | ||||||||||||
| Approach A q2a | 1.061 | 0.984–1.145 | 1.063 | 0.993–1.139 | 0.952 | 0.863–1.049 | 0.931 | 0.853–1.015 | ||||
| q3 | 1.056 | 0.976–1.142 |
|
| 0.964 | 0.872–1.065 | 0.990 | 0.908–1.077 | ||||
| q4 | 1.026 | 0.945–1.113 | 1.034 | 0.969–1.103 | 1.005 | 0.911–1.108 | 0.990 | 0.917–1.070 | ||||
| Trend testb | 1.005 | 0.979–1.031 | 1.008 | 0.988–1.029 | 1.005 | 0.974–1.038 | 1.004 | 0.980–1.030 | ||||
| Approach B SPDEc | 1.009 | 0.926–1.095 | 1.005 | 0.929–1.083 | 0.981 | 0.887–1.081 | 0.980 | 0.880–1.077 | ||||
| NHL | ||||||||||||
| Approach A q2a | 1.022 | 0.944–1.106 | 1.013 | 0.939–1.092 | 1.049 | 0.972–1.132 | 1.050 | 0.974–1.131 | ||||
| q3 | 1.032 | 0.952–1.119 | 1.061 | 0.986–1.142 | 1.029 | 0.953–1.112 | 1.058 | 0.982–1.139 | ||||
| q4 | 0.994 | 0.915–1.080 | 0.987 | 0.919–1.059 | 1.076 | 0.997–1.161 |
|
| ||||
| Trend testb | 0.997 | 0.971–1.024 | 0.997 | 0.975–1.02 | 1.021 | 0.996–1.046 |
|
| ||||
| Approach B SPDEc | 0.994 | 0.915–1.080 | 0.984 | 0.909–1.067 | 1.062 | 0.985–1.132 | 1.064 | 0.988–1.143 | ||||
The table shows the results of the approaches A and B, broken down as follows: unadjusted (model n.1) and adjusted for socio-demographic variables and industrial emissions (model n.3)
aQuartiles: reference [6.46, 20.2], q2 [20.24, 25.0], q3 [24.99, 29.9] and q4 [29.86, 243.7 mg kg−1]
bRR, taking quartiles as a categorical variable
cRR for a change of one unit in the logarithm of the elements’ soil concentration
Summary of estimates of the effect (RR) of arsenic topsoil levels, categorised in quartiles, on mortality due to different tumour types, by sex
| Cancer site | Men | Women | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unadjusted | Adjusted | Unadjusted | Adjusted | |||||||||
| RR | 95 % | CI | RR | 95 % | CI | RR | 95 % | CI | RR | 95 % | CI | |
| Buccal cavity and pharynx | ||||||||||||
| Approach A q2a | 1.003 | 0.937–1.073 | 0.987 | 0.922–1.057 | 1.102 | 0.986–1.233 | 1.069 | 0.958–1.194 | ||||
| q3 | 1.018 | 0.943–1.099 | 1.048 | 0.977–1.123 | 1.042 | 0.918–1.183 | 1.050 | 0.931–1.184 | ||||
| q4 |
|
|
|
| 1.076 | 0.957–1.211 | 1.051 | 0.947–1.165 | ||||
| Trend testb |
|
|
|
| 1.018 | 0.980–1.057 | 1.012 | 0.979–1.046 | ||||
| Approach B SPDEc |
|
|
|
| 1.053 | 0.974–1.144 | 1.048 | 0.971–1.137 | ||||
| Oesophagus | ||||||||||||
| Approach A q2a | 0.976 | 0.910–1.046 | 0.951 | 0.887–1.021 | 0.920 | 0.789–1.073 | 0.865 | 0.738–1.012 | ||||
| q3 | 0.959 | 0.887–1.038 | 1.004 | 0.935–1.078 | 0.912 | 0.766–1.085 | 0.925 | 0.783–1.091 | ||||
| q4 | 1.030 | 0.952–1.115 |
|
| 1.020 | 0.866–1.198 | 1.092 | 0.948–1.26 | ||||
| Trend testb | 1.010 | 0.984–1.037 |
|
| 1.010 | 0.957–1.066 | 1.043 | 0.996–1.093 | ||||
| Approach B SPDEc | 1.032 | 0.978–1.095 | 1.026 | 0.971–1.088 | 1.052 | 0.938–1.178 | 1.042 | 0.926–1.167 | ||||
| Stomach | ||||||||||||
| Approach A q2a | 1.012 | 0.965–1.062 | 1.005 | 0.957–1.056 | 0.980 | 0.925–1.039 | 0.994 | 0.939–1.053 | ||||
| q3 | 1.002 | 0.947–1.060 | 1.012 | 0.962–1.064 | 0.974 | 0.911–1.041 | 0.996 | 0.939–1.057 | ||||
| q4 | 1.054 | 0.994–1.117 |
|
| 0.990 | 0.925–1.060 |
|
| ||||
| Trend testb | 1.017 | 0.997–1.036 |
|
| 0.997 | 0.975–1.020 |
|
| ||||
| Approach B SPDEc | 1.035 | 0.994–1.079 | 1.028 | 0.986–1.073 | 1.015 | 0.970–1.069 | 1.014 | 0.964–1.064 | ||||
| Colorectal | ||||||||||||
| Approach A q2a |
|
| 1.029 | 0.995–1.065 | 1.010 | 0.972–1.05 | 1.011 | 0.976–1.047 | ||||
| q3 |
|
|
|
| 0.990 | 0.948–1.034 | 1.001 | 0.966–1.038 | ||||
| q4 |
|
|
|
| 1.004 | 0.960–1.049 | 1.004 | 0.972–1.037 | ||||
| Trend testb |
|
|
|
| 1.000 | 0.985–1.014 | 1.000 | 0.990–1.011 | ||||
| Approach B SPDEc |
|
| 1.026 | 0.996–1.057 | 1.008 | 0.976–1.039 | 0.996 | 0.968–1.026 | ||||
| Liver | ||||||||||||
| Approach A q2a | 0.995 | 0.913–1.083 | 0.866 | 0.801–0.936 | 1.082 | 0.957–1.224 | 0.881 | 0.781–0.992 | ||||
| q3 | 0.987 | 0.896–1.087 | 0.907 | 0.838–0.981 | 0.953 | 0.827–1.097 | 0.863 | 0.762–0.978 | ||||
| q4 |
|
| 1.063 | 0.990–1.141 | 1.059 | 0.918–1.223 | 0.928 | 0.831–1.036 | ||||
| Trend testb |
|
|
|
| 1.009 | 0.963–1.058 | 0.979 | 0.945–1.015 | ||||
| Approach B SPDEc |
|
| 1.048 | 0.979–1.135 | 0.984 | 0.893–1.087 | 0.938 | 0.856–1.042 | ||||
| Pancreas | ||||||||||||
| Approach A q2a | 1.044 | 0.991–1.099 | 1.029 | 0.979–1.081 | 1.050 | 0.992–1.111 | 1.023 | 0.971–1.078 | ||||
| q3 | 0.989 | 0.932–1.049 | 1.001 | 0.950–1.055 | 1.029 | 0.966–1.097 | 1.040 | 0.984–1.099 | ||||
| q4 | 1.060 | 0.999–1.124 |
|
| 1.053 | 0.988–1.122 |
|
| ||||
| Trend testb | 1.015 | 0.996–1.035 |
|
| 1.014 | 0.993–1.035 |
|
| ||||
| Approach B SPDEc |
|
| 1.029 | 0.991–1.069 | 1.010 | 0.966–1.056 | 1.002 | 0.961–1.047 | ||||
| Larynx | ||||||||||||
| Approach A q2a | 0.951 | 0.890–1.016 | 0.928 | 0.868–0.991 | 0.975 | 0.773–1.227 | 0.973 | 0.766–1.233 | ||||
| q3 | 0.963 | 0.891–1.04 | 0.931 | 0.868–0.997 | 0.873 | 0.665–1.137 | 0.914 | 0.689–1.204 | ||||
| q4 | 1.013 | 0.937–1.096 | 1.014 | 0.953–1.079 | 1.096 | 0.897–1.34 | 1.040 | 0.838–1.293 | ||||
| Trend testb | 1.006 | 0.980–1.032 | 1.007 | 0.987–1.027 | 1.028 | 0.963–1.098 | 1.013 | 0.944–1.087 | ||||
| Approach B SPDEc | 1.011 | 0.955–1.068 | 1.012 | 0.958–1.071 | 1.053 | 0.888–1.216 |
|
| ||||
| Lung | ||||||||||||
| Approach A q2a | 0.994 | 0.962–1.027 | 0.990 | 0.961–1.019 |
|
| 1.036 | 0.977–1.098 | ||||
| q3 | 1.001 | 0.962–1.041 | 1.004 | 0.974–1.034 |
|
|
|
| ||||
| q4 | 1.018 | 0.976–1.062 |
|
|
|
|
|
| ||||
| Trend testb | 1.006 | 0.992–1.021 |
|
|
|
|
|
| ||||
| Approach B SPDEc | 1.014 | 0.982–1.049 | 1.008 | 0.978–1.039 |
|
| 1.037 | 0.976–1.089 | ||||
| Prostate | ||||||||||||
| Approach A q2a | 1.005 | 0.967–1.044 |
|
| ||||||||
| q3 | 0.990 | 0.948–1.033 | 1.027 | 0.989–1.065 | ||||||||
| q4 | 0.984 | 0.942–1.029 |
|
| ||||||||
| Trend testb | 0.994 | 0.980–1.008 |
|
| ||||||||
| Approach B SPDEc | 0.994 | 0.964–1.025 | 0.993 | 0.961–1.023 | ||||||||
| Kidney | ||||||||||||
| Approach A q2a | 1.051 | 0.980–1.127 | 0.983 | 0.919–1.051 | 0.969 | 0.886–1.061 | 0.933 | 0.861–1.011 | ||||
| q3 | 1.077 | 0.996–1.166 | 1.044 | 0.972–1.119 | 0.978 | 0.883–1.082 | 0.982 | 0.899–1.073 | ||||
| q4 |
|
|
|
| 0.985 | 0.894–1.084 | 0.970 | 0.900–1.045 | ||||
| Trend testb |
|
|
|
| 0.997 | 0.966–1.028 | 0.996 | 0.973–1.02 | ||||
| Approach B SPDEc |
|
| 1.052 | 0.999–1.107 | 0.995 | 0.930–1.058 | 0.982 | 0.921–1.046 | ||||
| Brain | ||||||||||||
| Approach A q2a |
|
|
|
| 1.063 | 0.989–1.142 | 1.037 | 0.966–1.114 | ||||
| q3 | 1.030 | 0.962–1.103 | 1.050 | 0.983–1.121 | 1.057 | 0.975–1.146 | 1.076 | 0.998–1.161 | ||||
| q4 |
|
|
|
|
|
|
|
| ||||
| Trend testb |
|
|
|
|
|
|
|
| ||||
| Approach B SPDEc |
|
|
|
|
|
| 1.051 | 0.997–1.107 | ||||
| NHL | ||||||||||||
| Approach A q2a | 1.019 | 0.945–1.098 | 0.989 | 0.920–1.063 |
|
| 1.033 | 0.962–1.108 | ||||
| q3 | 1.003 | 0.925–1.088 | 1.017 | 0.943–1.095 | 1.069 | 0.988–1.156 |
|
| ||||
| q4 | 1.043 | 0.962–1.129 |
|
|
|
|
|
| ||||
| Trend testb | 1.012 | 0.986–1.039 |
|
| 1.025 | 1.000–1.049 |
|
| ||||
| Approach B SPDEc | 1.032 | 0.976–1.087 | 1.019 | 0.961–1.074 | 1.049 | 0.998–1.108 | 1.035 | 0.986–1.090 | ||||
| Leukaemias | ||||||||||||
| Approach A q2a | 1.030 | 0.973–1.091 | 0.995 | 0.941–1.051 | 1.024 | 0.963–1.090 | 0.985 | 0.929–1.045 | ||||
| q3 | 1.046 | 0.983–1.114 | 1.035 | 0.976–1.097 | 1.012 | 0.944–1.085 | 0.990 | 0.929–1.056 | ||||
| q4 |
|
| 1.031 | 0.978–1.086 | 1.027 | 0.964–1.095 | 0.991 | 0.935–1.048 | ||||
| Trend testb |
|
| 1.012 | 0.996–1.029 | 1.007 | 0.987–1.028 | 0.998 | 0.980–1.016 | ||||
| Approach B SPDEc |
|
|
|
| 1.011 | 0.970–1.061 | 1.003 | 0.960–1.054 | ||||
The table shows the results of the approaches A and B, broken down as follows: unadjusted (model n.1) and adjusted for socio-demographic variables and industrial emissions (model n.3)
aQuartiles: reference [1.00, 9.11], q2 [9.11, 12.82], q3 [12.82, 16.97] and q4 [16.97, 99.37 mg kg−1]
bRR, taking quartiles as a categorical variable
cRR for a change of one unit in the logarithm of the elements’ soil concentration